HCPCS Level II · Drugs administered other than oral method
J1452Injection, fomivirsen sodium, intraocular, 1.65 mg
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1452
J1452 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, fomivirsen sodium, intraocular, 1.65 mg.
It was added to HCPCS effective 01/01/2001, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Intraocular fomivirsen na
- Date added
- 01/01/2001
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J14xx codes
- J1410Injection, estrogen conjugated, per 25 mg
- J1411Injection, etranacogene dezaparvovec-drlb, per therapeutic dose
- J1412Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes
- J1413Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
- J1414Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
- J1426Injection, casimersen, 10 mg
- J1427Injection, viltolarsen, 10 mg
- J1428Injection, eteplirsen, 10 mg
- J1429Injection, golodirsen, 10 mg
- J1430Injection, ethanolamine oleate, 100 mg
- J1434Injection, fosaprepitant (focinvez), 1 mg
- J1435Injection, estrone, per 1 mg
Common questions about J1452
Is HCPCS J1452 still valid?
- No. J1452 was terminated on 12/31/2025.
Does Medicare cover J1452?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.